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Individuals with systemic lupus erythematosus (SLE) 1 or one of several other 
rheumatic autoimmune diseases exhibit a  number of immunological abnormali- 
ties, including the production of antibodies directed against components of cell 
nuclei (1). The specificities of these antinuclear antibodies have been extensively 
investigated for the purpose of understanding  the pathogenesis of the diseases 
as well as  for use as diagnostic aids.  Antibodies against  DNA,  histories,  and  a 
growing list of nonhistone  nuclear proteins  have been identified in  the sera of 
SLE patients  (2).  However, at the present  time,  RNA polymerase I  (3) and an 
associated enzyme, protein kinase NII (4), are the only two nonhistone nuclear 
protein target antigens of SLE autoantibodies for which enzymatic activities are 
known. Antibodies against RNA polymerase I have been demonstrated (3) in the 
sera of all SLE and mixed connective tissue disease patients tested, as well as in 
the sera of 78% of individuals with rheumatoid arthritis.  Because the structure 
and  function  of RNA polymerase I  are well documented (reviewed in  5),  this 
enzyme provides a  unique  tool  for  investigating  the  mechanism  of rheumatic 
disease autoimmunity. 
RNA polymerase I is a complex enzyme composed of eight different subunits 
(S1-$8)  (5).  The  specificities  of  the  autoantibodies  for  RNA  polymerase  I 
subunits appear to be characteristic of the particular rheumatic disease (3). Thus, 
only anti-S3 was found in the sera of rheumatoid arthritis patients, whereas sera 
from SLE patients contained anti-S3 plus anti-S2 and/or anti-S5, and sera from 
individuals  with  mixed  connective  tissue disease contained  anti-S4  alone  or in 
combination  with anti-S3 and anti-S5.  This data demonstrated  the nonrandom 
nature  of the rheumatic  disease autoimmune  response and raised the question 
of why $2,  $3,  $4,  and  $5  were more autoimmunogenic  than  the  other  four 
polymerase polypeptides.  Subsequent studies  demonstrated  (6,  7) that  $2,  $3, 
and $5 were by far the most highly phosphorylated subunits, and that $4 and $5 
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were  related  to  protein  kinase  Nil  (4-7).  Further,  the  immunoreactivity of 
polymerase polypeptides with SLE patient antibodies was shown (8) to be greatly 
enhanced by  prior  phosphorylation of the  enzyme with  protein  kinase  NII. 
Conversely,  in  vitro  dephosphorylation  of RNA  polymerase  I  with  alkaline 
phosphatase reduced the reaction of the autoantibodies with the polymerase by 
40-50%.  These data indicated that a  significant fraction of the SLE autoanti- 
bodies against RNA polymerase I are directed against phosphorylated sites on 
the enzyme, and suggested that protein phosphorylation may have a major role 
in the production of autoimmunogenic polypeptides in the rheumatic diseases. 
To study the  mechanism(s) of RNA  polymerase  I  autoimmunogenicity, we 
have  chosen  an  animal  model.  Although  several  murine  strains  have  been 
developed that spontaneously develop syndromes resembling human SLE (9- 
12), anti-Sm antibodies are found almost uniquely in the related MRL lpr/lpr 
(MRL/lpr) and MRL +/+ (MRL/++) strains (13). Because anti-Sin is considered 
a  marker for human SLE (2),  these strains appeared to be the ones most likely 
to produce anti-RNA polymerase I  autoantibodies. The MRL/lpr  and MRL/ 
++ strains, developed by Murphy and Roths (10, 11) of The Jackson Laboratory, 
Bar Harbor,  ME, and their coworkers (12),  share 90%  of their genome. Both 
sexes of either strain produce anti-DNA and anti-nuclear antibodies, and develop 
chronic immune complex glomerulonephritis and necrotizing arteritis. MRL/lpr 
mice also exhibit massive generalized lymph node enlargement and die of the 
disease at an average age of ~20 wk. In contrast, MRL/++ mice do not develop 
generalized lymphoproliferation, and the onset of lupus-like disease is delayed 
so that death occurs much later, at an average age of 20 too. 
As the first step in using the MRL/lpr and MRL/++ mice as models of human 
RNA polymerase I autoimmunogenicity, we have screened the sera from these 
animals over a  period of ~30  wk for the presence of anti-RNA polymerase I 
antibodies. We report here that anti-RNA polymerase I antibodies are produced 
by all MRL/Ipr and MRL/++ mice, and that, like the onset of lupus-like disease, 
production of these antibodies is delayed in the MRL/++ mice. The presence of 
anti-RNA polymerase I antibodies thus appears to be a better indicator of the 
onset of the disease, at least in these animals, than either the presence of anti- 
DNA or anti-Sm antibodies. 
Materials and Methods 
Mice.  MRL]Ipr  and MRL/++ mice were obtained at the age of 5 wk from The Jackson 
Laboratory. Each individual mouse was bled from the tail, weekly for the first 14 wk of 
age, then less frequently for the next 16 wk. Sera were stored at -20°C and thawed only 
once before assay. 
Antigens.  RNA polymerase I was purified from isolated nuclei of the rat tumor, Morris 
hepatoma 3924A (7). After phenol extraction  of calf thymus DNA (Sigma Chemical Co., 
St. Louis, MO), single-stranded (ss) DNA was prepared by boiling for 10 min and rapidly 
cooling on ice. 
Radioimmunoassay.  Radioimmunoassays for the detection of anti-RNA polymerase I 
and anti-DNA antibodies have been described in detail previously (3,  14). Briefly, either 
100 ul of purified RNA polymerase I (2 ug) or ssDNA (50 #g) was adsorbed to 400 #1 
capacity, flat-bottomed  polystyrene  microtiter wells. Sera (100 t~l of l:10-diluted)  were 
then incubated in  the antigen-containing  wells, followed by quantitation of antibody 
binding with ~2~I-labeled (50 tzCi/#g) protein A (50,000 cpm/welt) and gamma counting. 1762  ANTI-RNA  POLYMERASE  I  ANTIBODIES  IN  MRL  AUTOIMMUNE  MICE 
The  use  of  ]2q-protein  A  was  superior  to  ]~5I-labeled anti-mouse  IgG  in  terms  of 
sensitivity and nonspecific binding (data not shown). Each determination was performed 
in duplicate. Sera from three  18-mo-old female BALB/c mice were pooled and used as 
the control. Backgrounds of 238  4-  19 and  617  4-  16  (cpm of ~25I-protein A  bound 4- 
SEM) were obtained with this pool in the radioimmunoassays for anti-RNA polymerase I 
and anti-ssDNA antibodies, respectively. Sera from five 5-wk-old MRL/++ mice produced 
a  mean value of 191  _  24 with RNA polymerase I as antigen. Similar background values 
were obtained with sera from a  number of BALB/c mice of both sexes, ranging in age 
from 6 wk to 2 yr (data not shown). None of the BALB/c control mice produced elevated 
values with RNA polymerase I as antigen. However, an occasional BALB/c serum sample 
contained significant anti-ssDNA antibodies (up to 2,500  cpm after subtraction of back- 
ground), as has been observed by others (12). MRL/lpr and MRL/++ mice were consid- 
ered positive for anti-RNA polymerase I and anti-DNA antibodies when values (cpm) at 
least twice those of the BALB/c control pool were obtained with sera from two consecutive 
bleedings. Results with  MRL  mouse  sera are expressed as the  quantity  (cpm) of l~5I- 
protein A  remaining bound to the wells, less the background. 
Results 
Anti-RNA Polymerase I Antibodies in MRL/lpr Mice.  Sera from  15  female and 
13  male MRL/lpr mice  were  screened  for anti-RNA  polymerase  I  antibodies. 
Anti-RNA  polymerase I antibodies were initially detected in the sera of 1 of the 
15  female MRL/lpr mice at the age of 5  wk (Fig.  1).  The  antibodies were  not 
detected  in any of the sera from male MRL/lpr mice until the age of 8  wk (Fig. 
1).  External  signs  of the  disease process,  such  as  lymph  node  enlargement  or 
alopecic dermatitis, were not evident until ~ 14 wk of age. There  was considerable 
variability among  the individual mice with regard  to the relative concentration 
of anti-RNA  polymerase  I  antibodies  (Fig.  2;  data  for  individual  female  mice 
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FIGURE  1.  Anti-RNA Polymerase I antibodies in sera of male and female MRL/lpr mice. 
Serum samples from male (0) and female (&) MRL/lDr mice, collected over a period of 27 
wk,  were analyzed for the presence of anti-RNA polymerase I antibodies as described in 
Materials and Methods. Results shown are the mean values of all determinations with male (n 
-- 13, initially) or female (n =  15, initially) animal sera. Numbers in the graph indicate the 
number of male or female mice with anti-RNA polymerase I antibodies, over the number of 
surviving mice. STETLER  ET  AL.  1763 
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FIGURE 2.  Anti-RNA polymerase I  antibodies in  sera of individual male MRL/lpr mice. 
Serum samples taken from male MRL/lpr mice at the ages indicated were analyzed for anti- 
RNA polymerase I antibodies as described in Materials and Methods. Results shown are the 
average  of duplicate  determinations with  sera  from  each  individual animal.  Each  symbol 
represents a different mouse. Slightly larger symbols indicate that the particular mouse died 
before the next bleeding. Numbers in the graph are those assigned randomly to the animal at 
the beginning of the experiment. 
not shown). Nevertheless, all MRL/lpr mice had detectable anti-RNA polymer- 
ase I antibodies in their sera before death. The antibodies were present in the 
sera of 100% of female and male mice by the age of 13 wk. In general, females 
produced the antibodies earlier (mean, 9.5 wk) as compared to males (mean, 9.7 
wk),  and  at  higher  relative  concentrations than  males  (Fig.  1).  One-third  of 
females had the antibodies before they were detected in any of the males. Neither 
the time of appearance nor the relative concentration of anti-RNA polymerase 
I antibodies correlated with age at time of death (see Fig. 2). 
Anti-ssDNA Antibodies in MRL/lpr Mice.  Antibodies against ssDNA were de- 
monstrable in the sera of all female and 11  of the 13 male MRL/lpr mice at the 
age of 5 wk (Fig. 3).  The antibodies were absent only in the sera of male mice 
numbers 1 and 5 at this time (not shown). However, by 6 wk of age, these animals 
also had anti-ssDNA antibodies in their sera.  As was observed with anti-RNA 
polymerase I antibodies, females produced slightly higher serum concentrations 
of anti-ssDNA antibodies than did the males (Fig. 3). There was less variability 
among individual animals with  respect  to relative concentration of anti-DNA 
antibodies (not shown) than was observed with anti-RNA polymerase I.  How- 1764  ANTI-RNA  POLYMERASE  I  ANTIBODIES  IN  MRL  AUTOIMMUNE  MICE 
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FIGURE  3.  Anti-ssDNA antibodies in sera of male and female MRL/lpr  mice. Sera from male 
(Q) and  female (A) MRL/lpr mice were analyzed  for anti-ssDNA antibodies as described  in 
Materials  and  Methods.  Results shown are  the  means of the  determinations with  male  or 
female animal sera. 
ever,  there  was  no  correlation  between  relative concentration of anti-ssDNA 
antibodies and severity of external disease symptoms or age of death. Similarly, 
there was no apparent correlation between relative concentration of anti-ssDNA 
and anti-RNA polymerase I antibodies. In 27 of the 28  mice tested, detection 
of anti-ssDNA antibodies preceded detection of anti-RNA polymerase I  anti- 
bodies. Antibodies of both specificities were present at the earliest time tested (5 
wk) in one female MRL/lpr mouse. 
Anti-RNA Polymerase I and Anti-ssDNA Antibodies in MRL/++ Mice.  Three of 
the five MRL/++ mice tested (male) had anti-ssDNA antibodies in their sera at 
5  wk  of age  (Fig.  4A  and  Fig.  5).  Like the  MRL/lpr  mice, all  the  MRL/++ 
animals had  these antibodies by 6  wk.  Up  to  ~11  wk of age,  the mean anti- 
ssDNA antibody concentration of the male MRL/++ animals was very similar to 
that of the male MRL/lpr mice (compare Fig. 5 with Fig. 3) even though onset 
of lupus-like disease is delayed in  MRL/++ (10-12).  No external signs of the 
disease were evident in these mice until 25 wk (see below). 
Anti-RNA polymerase I antibodies were not detected in the sera of MRL/++ 
mice for the first 9 wk of age (Fig. 4B). At 10 wk, serum from mouse number 2 
had anti-RNA polymerase I antibodies (2.3  times background). However, this 
reactivity had returned to background by  11  wk, and the animal was thus not 
considered positive for the antibodies at this time (see  Materials and Methods), 
Similar, short-duration bursts  of anti-RNA polymerase I  antibodies were ob- 
served in sera from animals 1 and 5 at 14 wk of age. Sera from animal number 
3 contained the antibodies on wk 13 and 14, and so was scored as positive at 13 
wk of age, even though only background levels  were observed until 23  wk of STETLER  ET  AL.  1765 
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FZGURE 4.  Anti-ssDNA  and anti-RNA polymerase I antibodies in sera of male MRL/++ 
mice. Anti-ssDNA and anti-RNA polymerase I antibodies in the sera of five male MRL/++ 
mice up to the age of 31 wk were quantitated  as described in Materials and Methods. Results 
are from duplicate determinations  of anti-ssDNA (A) or anti-RNA polymerase I (B) antibody 
content  in sera from each individual animal.  Results obtained  with sera  from each mouse 
(numbered  1-5) are indicated with a different symbol (0, &, m, A, and O, respectively). 
age. At 28 wk of age, sera from all five mice were considered positive for anti- 
RNA polymerase I  antibodies  (mean age,  22.8  wk).  Hence,  unlike  anti-ssDNA 
antibody production,  anti-RNA  polymerase I antibody production was delayed 
in  MRL/++  male mice more  than  3  mo as compared  to MRL/lpr male mice. 
Mouse  number  3  (Fig.  4B)  exhibited  minor  alopecia at  age  25  wk,  while  the 
remaining four MRL/++  mice appeared normal. 
A  precipitous  decrease  in  anti-ssDNA  antibodies  was  observed  in  the 
MRL/++  mice at the  age of about  20  wk (Fig.  4A  and  Fig.  5).  This drop was 
followed by the  appearance  in  the  sera of anti-RNA  polymerase I  antibodies. 
Interestingly,  the  decrease  at  this  time  in  each  individual  animal's  anti-DNA 
antibodies was directly proportional  (R  2  =  0.964)  to the following initial rise in 
anti-RNA  polymerase I  (Fig.  6), suggesting a  possible relationship between the 
two phenomena. Smaller decreases, of shorter duration, in anti-ssDNA antibodies 
were  observed  at  ~9-10  and  13-14  wk  of age  (Fig.  4A  and  Fig.  5),  which 
corresponded  to  short-duration  bursts  of anti-RNA  polymerase  I  antibodies 
described  in  the  preceding  paragraph.  Although  the  appearance  of anti-RNA 
polymerase I  antibodies in  several of the MRL/lpr mice was accompanied by a 1766  ANTI-RNA  POLYMERASE  I  ANTIBODIES  IN  MRL  AUTOIMMUNE  MICE 
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FIGURE 5.  Means of serum anti-ssDNA (O)  or anti-RNA polymerase I  (A) antibodies of 
MRL/++ mice as a group. Numbers in the graph indicate the number of mice in which anti- 
RNA polymerase I was detected at that particular age. 
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FIGURE  6.  Correlation of decrease in anti-ssDNA antibodies with appearance of anti-RNA 
polymerase I  antibodies in sera of MRL/++  mice. The log of the decrease in anti-ssDNA 
antibodies from each MRL/++ mouse serum was plotted against the log of the increase in 
anti-RNA polymerase I antibodies. The decrease in anti-ssDNA antibodies was figured from 
the time the quantity of these antibodies began to decline precipitously (16 wk for mouse 3, 
20 wk for the other four mice) to the time the quantity of these antibodies began to increase 
or anti-RNA polymerase I antibodies appeared in the sera (23 wk for mouse 3, 27 wk for the 
other four mice). The quantities of anti-RNA polymerase I antibodies at 23 wk for mouse 3 
and at  27  wk for the other four mice were used in the plot. The line was  fitted by linear 
regression analysis" (R  2 =  0.964).  Numbers in the graph refer to the identification number 
assigned to each animal. 
drop  in  anti-DNA  antibodies  (not  shown),  a  direct  proportionality  was  not 
evident. The accelerated disease process in the MRL/lpr animals may necessitate 
more frequent serum samples to observe such a relationship. 
Discussion 
All mice of the autoimmune strains MRL/lpr (n =  28) and MRL/++ (n =  5) 
were  found to produce anti-RNA  polymerase  I antibodies.  The presence of STETLER  ET  AL.  1767 
these antibodies in  the sera is yet another  characteristic  of human  SLE that  is 
shared by these two murine  strains.  Eisenberg et al.  (13) reported  earlier  that 
MRL mice also produce anti-Sm antibodies, a specificity found almost exclusively 
in human  SLE. However, unlike anti-RNA polymerase I antibodies, which are 
found in  100%  of both human  (3) and  MRL-murine  lupus,  anti-Sm  has been 
demonstrated in only 30-40% of human  (2) and MRL-murine (13) lupus popu- 
lations.  Further,  anti-Sm antibodies were not detected in the sera of MRL/lpr 
mice until the age of 4 mo (13) when the disease is already quite advanced (10, 
11),  and  many  of  the  animals  were  moribund  (13).  In  contrast,  anti-RNA 
polymerase I antibodies were detected in the sera of >50% of MRL/lpr mice at 
the early age of 10 wk, and in  100% by 13 wk of age. This time of appearance 
of anti-RNA polymerase I antibodies (mean, 9.6 wk of age for males and females 
combined)  corresponds  to  the  reported  (10-12)  onset  of massive  generalized 
lymph node enlargement in these animals at ~8 wk of age. It should be pointed 
out that anti-Sm antibodies were detected by use of the double immunodiffusion 
technique (13) while anti-RNA  polymerase I antibodies were quantitated  here 
by use of radioimmunoassay.  Whether  use of a  radioimmunoassay would allow 
earlier  detection  of anti-Sm  or  detection  in  a  larger  proportion  of MRL/lpr 
animals, is not certain. 
We recently reported  (14) that  immunization  of rabbits with  purified  RNA 
polymerase  I  resulted  in  the production  of anti-DNA  antibodies  shortly  after 
production  of antibodies  against  the  enzyme.  RNA  polymerase  I  has  a  high 
affinity for DNA, inherent  to its functional role in transcription.  We therefore 
proposed that  the injected, immunogenic  RNA polymerase I had become asso- 
ciated with the DNA present in blood plasma (15), which led to induction of an 
immune response against  the normally  nonimmuogenic  (16) nucleic acid com- 
ponent of the complex. The immunogenic property of nucleic acids when they 
are complexed with protein  has been well established (17).  Because antibodies 
against  RNA polymerase I  and  DNA are both characteristic  of SLE (1-3),  we 
suggested (14) that a similar mechanism may be involved in the induction ofanti- 
DNA antibody formation in rheumatic disease. In this study, significant quantities 
of anti-DNA antibodies were present in the sera of all but one of the MRL/lpr 
and  MRL/++  mice before anti-RNA polymerase I antibodies could be found. 
At least two factors could explain why anti-DNA antibodies were detected earlier 
in these mice. First, a relatively small quantity of immunogenic RNA polymerase 
I  complexed  with  DNA  in  the  sera  of the  mice  could  conceivably induce  an 
immune  response  against  the  nucleic  acid,  which  then  would  develop  more 
rapidly than the response against the enzyme itself, due to a higher level of DNA 
in  blood plasma.  Antibodies  against  RNA  polymerase  I  were detected before 
those  against  nucleic  acids  in  rabbits  immunized  with  the  enzyme  (14),  most 
likely because of the availability of excess quantities of injected enzyme. Second, 
it is possible that anti-RNA polymerase I antibodies were produced at an earlier 
time, but that they were complexed with antigen and thus not detectable as free 
serum antibodies. The fact that anti-RNA polymerase I antibodies decreased in 
relative concentration  in the sera of MRL/++ mice whenever anti-ssDNA anti- 
bodies increased, and vice versa, suggests that anti-RNA polymerase I antibodies 
may have been produced at an earlier time than 5 wk, but either became bound 1768  ANTI-RNA  POLYMERASE  I  ANTIBODIES  IN  MRL  AUTOIMMUNE  MICE 
to serum antigen or decreased to undetectable levels when anti-ssDNA antibodies 
began to increase rapidly. The important issue here is that a  relationship does 
seem to exist between anti-DNA and anti-RNA polymerase I antibodies. 
Perhaps the most significant finding of this investigation is that, like the onset 
of lupus-like disease (10-12),  the appearance of serum anti-RNA polymerase I 
antibodies was  delayed ~3  mo in  MRL/++ compared to MRL/lpr mice. The 
age of appearance of anti-Sin antibodies in the sera appears to be about the same 
in  the  two  strains  (13).  Similarly,  the  age  of first  appearance  and  relative 
concentration of anti-DNA antibodies in the sera of the MRL/++ mice was not 
much different than that observed with the MRL/lpr  mice. These results suggest 
that anti-DNA antibodies by themselves are neither reliable indicators of lupus- 
like disease, nor solely responsible for disease symptoms. The relatively common 
occurence of anti-DNA antibodies in the sera of immunologically normal mice 
(12)  and  humans  with  no  apparent  autoimmune disease  (18)  supports  this 
contention. Thus,  if anti-DNA antibodies are  involved in the disease process, 
some other factor(s) must also be present to elicit disease symptoms. Anti-RNA 
polymerase I antibodies were present in the sera of all MRL/lpr mice before or 
at  the time of onset of external  disease  symptoms such  as  gross  lymph node 
enlargement and alopecic dermatitis. These symptoms, as well as detectable anti- 
RNA polymerase I antibodies were absent in MRL/++ animals for more than 5 
mo. Interestingly, one of the MRL/++ mice (mouse number 3) began exhibiting 
minor alopecia at an age of ~24 wk, just after the appearance and sharp increase 
of anti-RNA polymerase I  serum antibodies.  The other four MRL/++ mice 
exhibited no external disease symptoms at this time, and had little or no anti- 
RNA  polymerase  I  antibodies  in  their  sera.  Even  more  intriguing  was  the 
apparent direct relationship between the decrease in anti-DNA antibody concen- 
tration  in  the  sera  of the  MRL/++  mice  and  the  appearance  of anti-RNA 
polymerase I antibodies. This decrease in free anti-DNA antibodies in the sera 
may indicate that these antibodies are forming complexes with antigen and are 
being cleared from the sera. How RNA polymerase I antigen and antibody could 
be involved in this process is only conjecture at this point. However, the direct 
proportionality of the  anti-DNA  antibody decrease  with  the  appearance  and 
increase in anti-RNA polymerase I antibodies seems to be too close (R 2 ----- 0.964) 
for a  fortuitous relationship.  Clearly, the  relationship of anti-DNA and anti- 
RNA polymerase I  antibodies, and the interaction of the two antigens in  the 
rheumatic disease process deserves further study. The MRL/lpr and MRL/++ 
autoimmune murine strains will be invaluable to this endeavor. 
Summary 
Sera from individual MRL/Ipr  and MRL/++ mice, which develop an autoim- 
mune  disease  similar  to  human  systemic  lupus  erythematosus  (SLE),  were 
screened over a period of ~30 wk for the presence of anti-RNA polymerase I 
and  anti-ssDNA  antibodies.  Even  though  onset  of the  disease  is  delayed  in 
MRL/++ as compared to MRL/lpr  mice, anti-ssDNA antibodies were present in 
comparable concentrations in the sera of all mice by the age of 6 wk. As observed 
iff sera of human SLE patients, anti-RNA polymerase I antibodies were detected 
in the sera of all MRL mice. However, unlike the anti-ssDNA antibodies, anti- STETLER  ET  AL.  1769 
RNA polymerase I antibodies were detected much later in MRL/++  mice (mean 
age, 22.8  wk) as compared to MRL/lpr  mice (mean age, 9.6 wk). The presence 
of anti-RNA  polymerase  I  antibodies  in  sera  of MRL  mice was  thus  a  much 
better  indicator  of disease  status  than  the  presence  of anti-ssDNA  antibodies. 
The appearance and  increase  in anti-RNA  polymerase I  antibodies in the sera 
of MRL/++  mice correlated  (R  2 =  0.964)  with a  precipitous decrease  in  anti- 
ssDNA antibodies, starting at about 20 wk of age. These results suggest a possible 
relationship between the RNA polymerase I and DNA autoimmune reactions. 
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